BioInvent International AB (publ) (BOVNF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, BioInvent International AB (publ) (BOVNF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 51/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 18 mar 2026BioInvent International AB (publ) (BOVNF) Resumen de Asistencia Médica y Tuberías
BioInvent International AB, a Swedish clinical-stage biotech firm, specializes in immuno-modulatory antibodies for cancer. Its lead candidate, BI-1206, targets non-Hodgkin lymphoma and solid tumors, supported by strategic collaborations with Pfizer and Merck. The company operates in a competitive landscape, focusing on novel cancer therapies.
Tesis de Inversión
BioInvent International AB presents a compelling investment case based on its innovative immuno-oncology pipeline and strategic collaborations. The lead drug candidate, BI-1206, holds significant potential in the treatment of non-Hodgkin lymphoma and solid tumors, with ongoing clinical trials providing key data points. The collaborations with Pfizer and Merck validate the company's technology and provide financial support for development programs. With a market capitalization of $0.22 billion, BioInvent offers exposure to the high-growth immuno-oncology market. Upcoming clinical trial results for BI-1206 and other pipeline assets represent potential catalysts for value appreciation. However, the company's negative P/E ratio of -4.51 and negative profit margin of -147.0% highlight the risks associated with clinical-stage biotechnology companies, including the uncertainty of regulatory approvals and the need for additional funding.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Lead drug candidate BI-1206 is in clinical development for non-Hodgkin lymphoma and solid tumors, representing a significant potential revenue stream.
- Strategic collaboration with Pfizer Inc. to develop antibodies against tumor-associated myeloid cells, providing financial and scientific validation.
- Partnership with Transgene to co-develop multi-functional oncolytic viruses for solid tumor treatment, expanding the company's therapeutic modalities.
- Collaboration and supply agreement with Merck for clinical development of BI-1808, enhancing the drug's development and market reach.
- Gross margin of 98.5% indicates strong potential profitability upon successful commercialization of its drug candidates.
Competidores y Pares
Fortalezas
- Innovative immuno-oncology pipeline with novel drug candidates.
- Strategic collaborations with major pharmaceutical companies.
- Strong intellectual property portfolio.
- Experienced management team with expertise in drug development.
Debilidades
- Limited financial resources as a clinical-stage company.
- Dependence on partnerships for late-stage development and commercialization.
- High risk of clinical trial failures.
- Negative profitability and reliance on external funding.
Catalizadores
- Upcoming: Clinical trial results for BI-1206 in non-Hodgkin lymphoma and solid tumors.
- Upcoming: Progress in the development of anti-TNFR2 antibodies BI-1808 and BI-1910.
- Ongoing: Expansion of strategic collaborations and partnerships with pharmaceutical companies.
- Ongoing: Advancement of novel immuno-oncology assets through preclinical and clinical development.
- Ongoing: Potential for regulatory approvals and commercialization of drug candidates.
Riesgos
- Potential: Clinical trial failures and setbacks in drug development.
- Potential: Competition from other biotechnology and pharmaceutical companies.
- Potential: Regulatory hurdles and delays in drug approval.
- Ongoing: Limited financial resources and dependence on external funding.
- Ongoing: Economic downturn and reduced healthcare spending.
Oportunidades de crecimiento
- Expansion of BI-1206 Clinical Trials: BioInvent has the opportunity to expand the clinical trials for BI-1206 to include additional cancer types and patient populations. This could significantly increase the potential market for the drug, which is currently focused on non-Hodgkin lymphoma and solid tumors. The global market for lymphoma treatment is projected to reach $17.9 billion by 2027, presenting a substantial opportunity for BioInvent. Success in these expanded trials could lead to accelerated regulatory approval and commercialization.
- Advancement of Anti-TNFR2 Antibodies: The development of BI-1808 and BI-1910, anti-TNFR2 antibodies, represents another significant growth opportunity. These antibodies target solid tumors and cutaneous T-cell lymphoma, addressing a market with substantial unmet needs. The global market for T-cell lymphoma treatment is expected to grow to $2.5 billion by 2028. Positive clinical trial results for these antibodies could lead to valuable partnerships and licensing agreements.
- Strategic Collaborations and Partnerships: BioInvent can leverage its expertise in immuno-oncology to establish additional strategic collaborations and partnerships with pharmaceutical companies. These collaborations can provide financial resources, access to new technologies, and expanded market reach. The company's existing partnerships with Pfizer and Merck demonstrate its ability to attract and maintain valuable relationships within the industry. Pursuing further collaborations will be crucial for long-term growth and success.
- Expansion into New Geographic Markets: BioInvent has the opportunity to expand its operations into new geographic markets, particularly in Asia and Latin America. These regions offer significant growth potential due to increasing healthcare spending and a growing prevalence of cancer. Establishing a presence in these markets would require strategic partnerships and investments in local infrastructure, but could significantly increase the company's revenue and market share.
- Development of Novel Immuno-Oncology Assets: BioInvent can continue to invest in research and development to expand its pipeline of novel immuno-oncology assets. This includes exploring new targets and mechanisms of action, as well as developing innovative drug delivery systems. By staying at the forefront of scientific innovation, BioInvent can maintain a competitive advantage and capitalize on emerging opportunities in the immuno-oncology market. The company's focus on tumor-associated myeloid cells and cancer-associated regulatory T cells positions it well to develop groundbreaking therapies.
Oportunidades
- Expansion of clinical trials to new cancer types and patient populations.
- Advancement of anti-TNFR2 antibodies for solid tumors and cutaneous T-cell lymphoma.
- Establishment of new strategic collaborations and partnerships.
- Expansion into new geographic markets.
Amenazas
- Competition from other biotechnology and pharmaceutical companies.
- Regulatory hurdles and delays in drug approval.
- Uncertainty of clinical trial outcomes.
- Economic downturn and reduced healthcare spending.
Ventajas competitivas
- Proprietary immuno-modulatory antibody technology platform.
- Strong intellectual property portfolio protecting its drug candidates.
- Strategic collaborations with major pharmaceutical companies like Pfizer and Merck.
- Expertise in targeting the tumor microenvironment and modulating the immune system.
Acerca de BOVNF
BioInvent International AB (publ) was founded in 1996 and is headquartered in Lund, Sweden. The company operates as a clinical-stage biotechnology firm dedicated to the discovery and development of novel immuno-modulatory antibodies for cancer therapy. BioInvent's primary focus is on addressing unmet needs in the treatment of various cancers through innovative research and development. Their lead drug candidate, BI-1206, is currently in clinical development for the treatment of non-Hodgkin lymphoma and solid tumors. This antibody is designed to target and modulate the tumor microenvironment, enhancing the body's immune response against cancer cells. Beyond BI-1206, BioInvent is also developing a portfolio of other immuno-oncology assets, including antibodies targeting tumor-associated myeloid cells, cancer-associated regulatory T cells, BT-001 in solid tumors, and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. These programs reflect the company's commitment to exploring multiple avenues for immunotherapy. BioInvent has established strategic collaborations with major pharmaceutical companies, including Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells, Transgene for co-developing multi-functional oncolytic viruses, and Merck for the clinical development of BI-1808. These partnerships provide valuable resources and expertise to support the advancement of BioInvent's pipeline. The company operates internationally, with a focus on markets in Sweden, Europe, the United States, and Japan.
Qué hacen
- Discovers and develops immuno-modulatory antibodies for cancer treatment.
- Focuses on therapies that harness the body's immune system to fight cancer.
- Develops BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors.
- Develops antibodies targeting tumor-associated myeloid cells.
- Develops antibodies targeting cancer-associated regulatory T cells.
- Develops BT-001 for solid tumors.
- Develops BI-1808 and BI-1910, anti-TNFR2 antibodies, for solid tumors and cutaneous T-cell lymphoma.
Modelo de Negocio
- Develops and patents novel immuno-oncology therapies.
- Out-licenses or co-develops drug candidates with pharmaceutical partners.
- Generates revenue through milestone payments, royalties, and supply agreements.
- Focuses on early-stage research and clinical development, partnering for late-stage commercialization.
Contexto de la Industria
BioInvent operates within the highly competitive and rapidly evolving biotechnology industry, specifically in the immuno-oncology segment. This segment focuses on developing therapies that harness the body's immune system to fight cancer. The market is characterized by intense research and development activity, with numerous companies vying to develop innovative treatments. Key trends include the increasing use of combination therapies, the development of personalized medicine approaches, and the exploration of novel targets and mechanisms of action. BioInvent's focus on immuno-modulatory antibodies positions it within this dynamic landscape, with the potential to capture a share of the growing market for cancer immunotherapies. Competitors include companies like AVCTF, CLVLY, CYDY, GSGTF, and HLOSF, each pursuing different approaches to cancer treatment.
Clientes Clave
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Patients suffering from various types of cancer, particularly non-Hodgkin lymphoma and solid tumors.
- Healthcare providers who prescribe and administer cancer therapies.
- Research institutions and academic centers involved in cancer research.
Finanzas
Gráfico e información
Precio de la acción de BioInvent International AB (publ) (BOVNF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BOVNF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BOVNF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BOVNF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BOVNF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Martin Welschof
CEO
Martin Welschof serves as the CEO of BioInvent International AB. His background includes extensive experience in the biotechnology and pharmaceutical industries. Before joining BioInvent, he held leadership positions at several biotech companies, focusing on drug development and commercialization. His expertise spans across various therapeutic areas, including oncology and immunology. He has a strong track record in strategic planning, business development, and fundraising.
Historial: Under Martin Welschof's leadership, BioInvent has advanced its pipeline of immuno-oncology assets, including BI-1206, through clinical development. He has also secured strategic collaborations with Pfizer and Merck, providing valuable resources and validation for the company's technology. His focus has been on driving innovation and building a sustainable business model. He manages 114 employees.
Información del mercado OTC de BOVNF
The OTC Other tier, where BioInvent International AB (BOVNF) trades, represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This contrasts with exchanges like the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Investing in OTC Other stocks carries higher risk due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in BOVNF.
- Low trading volume and wide bid-ask spreads can lead to price volatility and execution challenges.
- Lack of regulatory oversight increases the potential for fraud and manipulation.
- The company may not meet minimum listing requirements, indicating potential financial or operational issues.
- OTC Other stocks are generally considered more speculative and carry a higher risk of loss.
- Verify the company's financial statements and disclosures, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Confirm the company's registration and compliance with regulatory requirements.
- Strategic collaborations with reputable pharmaceutical companies like Pfizer and Merck.
- Clinical-stage development of immuno-oncology assets.
- Strong intellectual property portfolio.
- Experienced management team with expertise in drug development.
- Company incorporated in 1996, indicating a long operating history.
Lo Que los Inversores Preguntan Sobre BioInvent International AB (publ) (BOVNF)
¿Cuáles son los factores clave para evaluar BOVNF?
BioInvent International AB (publ) (BOVNF) actualmente tiene una puntuación IA de 51/100, indicando puntuación moderada. Fortaleza clave: Innovative immuno-oncology pipeline with novel drug candidates.. Riesgo principal a monitorear: Potential: Clinical trial failures and setbacks in drug development.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BOVNF?
BOVNF actualmente puntúa 51/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BOVNF?
Los precios de BOVNF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BOVNF?
La cobertura de analistas para BOVNF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BOVNF?
Las categorías de riesgo para BOVNF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures and setbacks in drug development.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BOVNF?
La relación P/E para BOVNF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BOVNF sobrevalorada o infravalorada?
Determinar si BioInvent International AB (publ) (BOVNF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BOVNF?
BioInvent International AB (publ) (BOVNF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of March 18, 2026.
- OTC market data may be limited and less reliable than exchange-listed data.
- Analyst consensus may not be available for all OTC stocks.